Clinical and laboratory studies over recent decades have established branched evolution as
a feature of cancer. However, while grounded in somatic selection, several lines of evidence …

Chronic myeloid leukemia (CML), caused by constitutively active BCR-ABL1 fusion tyrosine
kinase, has served as a paradigm for successful application of molecularly targeted cancer …

Advanced, anaplastic lymphoma kinase (ALK)–positive lung cancer is currently treated with
the first-generation ALK inhibitor crizotinib followed by more potent, second-generation ALK …

Background Ponatinib is a potent oral tyrosine kinase inhibitor of unmutated and mutated
BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor–refractory threonine-to …

Over the last decade, the notion that tumors are maintained by their own stem cells, the so-
called cancer stem cells, has created great excitement in the research community. This …

Glioblastoma multiforme (GBM), an aggressive tumor that typically exhibits treatment failure
with high mortality rates, is associated with the presence of cancer stem cells (CSCs) within …

The identification and characterization of cancer stem cells might lead to more effective
treatments for some cancers by focusing therapy on the most malignant cells. To achieve …

Dasatinib is a highly potent BCR-ABL inhibitor with established efficacy and safety in
imatinib-resistant/-intolerant patients with chronic myeloid leukemia (CML). In the phase 3 …

Background MDV3100 is an androgen-receptor antagonist that blocks androgens from
binding to the androgen receptor and prevents nuclear translocation and co-activator …

Inhibition of BCR-ABL by imatinib induces durable responses in many patients with chronic
myeloid leukemia (CML), but resistance attributable to kinase domain mutations can lead to …